Publications
58
Citations
809
Est. group size
~10
Recurring co-author estimate
Active years
13
Publishing since 2014
Shurui Cai's research focuses on how cancers driven by mutations in the RAS gene family, particularly KRAS, resist treatment and how new drugs can overcome this resistance. Recent work examines RAS-targeted inhibitors in lung cancer (NSCLC) and pancreatic cancer (PDAC), including how these drugs can be combined with immune-based therapies to make tumors more treatable.
Publication output has grown markedly over the past decade, rising from little to no activity before 2019 to a sharp increase in 2026, with an average of about 9 publications per year over the last 5 years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i> <i>G12C</i> -Mutant NSCLC for Immune Checkpoint Blockade
Cancer Discovery · 2026
- Figure 6 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Figure 5 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Supplementary Methods 1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Data from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Table S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Figure 3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Figure 2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Table S1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Supplementary Figures S1-S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Table S6 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Table S2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Figure 4 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Figure 1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Table S4 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory <i>KRAS</i><sup><i>G12C</i></sup>-Mutant NSCLC for Immune Checkpoint Blockade
2026
- Cancer Research×11
- Research Square×2
- Clinical Cancer Research×2
- Nature×1
- Molecular Cell×1
- Kari Kendra
Medicine · The Ohio State University
- Christin E. Burd
Medicine · The Ohio State University
- Lei Chen
Medicine · The Ohio State University
- Saba Shafi
Medicine · The Ohio State University
- Shreya Kumar
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile